Business Description
Merck KGaA
ISIN : DE0006599905
Share Class Description:
XSWX:MER: Ordinary SharesTotal Employee Number:
62,477Compare
Compare
Traded in other countries / regions
MRK.Germany0O14.UKMKKGY.USA1MRK.ItalyMRCK.AustriaMER.SwitzerlandMRK.BulgariaMRK1N.Mexico IPO Date
2014-11-03Description
Merck KGaA operates in three main segments: Life Science, Electronics, and Healthcare. The Life Science segment provides laboratory consumables and instruments to researchers in academia and applied fields, including the biopharmaceutical industry. The Electronics segment offers specialty materials to manufacture a variety of products, such as semiconductors and flat-screen televisions. In the healthcare segment, Merck develops, manufactures, and sells branded pharmaceuticals with significant therapeutic concentrations in oncology, multiple sclerosis, and fertility. In 1995, the E. Merck KG family publicly sold part of the company, resulting in the current 30% public ownership of the firm.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.31 | |||||
Equity-to-Asset | 0.56 | |||||
Debt-to-Equity | 0.41 | |||||
Debt-to-EBITDA | 2.02 | |||||
Interest Coverage | 8.72 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.02 | |||||
Beneish M-Score | -2.69 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -1.7 | |||||
3-Year EBITDA Growth Rate | -2.9 | |||||
3-Year EPS without NRI Growth Rate | -7.1 | |||||
3-Year FCF Growth Rate | -7 | |||||
3-Year Book Growth Rate | 3.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 4.67 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 3.53 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 95.75 | |||||
9-Day RSI | 91.35 | |||||
14-Day RSI | 89.35 | |||||
3-1 Month Momentum % | 17.32 | |||||
6-1 Month Momentum % | 1.32 | |||||
12-1 Month Momentum % | 1.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.51 | |||||
Quick Ratio | 1 | |||||
Cash Ratio | 0.4 | |||||
Days Inventory | 191.82 | |||||
Days Sales Outstanding | 73.35 | |||||
Days Payable | 80.06 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 1.56 | |||||
3-Year Dividend Growth Rate | 5.9 | |||||
Forward Dividend Yield % | 1.56 | |||||
5-Year Yield-on-Cost % | 2.82 | |||||
Shareholder Yield % | -0.22 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 58.53 | |||||
Operating Margin % | 17.15 | |||||
Net Margin % | 12.08 | |||||
EBITDA Margin % | 28.42 | |||||
FCF Margin % | 10.59 | |||||
OCF Margin % | 20.03 | |||||
ROE % | 8.71 | |||||
ROA % | 5.02 | |||||
ROIC % | 6.43 | |||||
3-Year ROIIC % | -41.69 | |||||
ROC (Joel Greenblatt) % | 28.7 | |||||
ROCE % | 8.82 | |||||
Years of Profitability over Past 10-Year | 10 | |||||
Moat Score | 7 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 24.98 | |||||
Forward PE Ratio | 17.28 | |||||
PE Ratio without NRI | 23.03 | |||||
Shiller PE Ratio | 21.33 | |||||
Price-to-Owner-Earnings | 24.18 | |||||
PEG Ratio | 10.01 | |||||
PS Ratio | 3.02 | |||||
PB Ratio | 2.13 | |||||
Price-to-Tangible-Book | 17.14 | |||||
Price-to-Free-Cash-Flow | 28.58 | |||||
Price-to-Operating-Cash-Flow | 15.09 | |||||
EV-to-EBIT | 19.73 | |||||
EV-to-Forward-EBIT | 21.62 | |||||
EV-to-EBITDA | 12.03 | |||||
EV-to-Forward-EBITDA | 14.84 | |||||
EV-to-Revenue | 3.42 | |||||
EV-to-Forward-Revenue | 3.48 | |||||
EV-to-FCF | 32.36 | |||||
Price-to-GF-Value | 1.04 | |||||
Price-to-Projected-FCF | 1.4 | |||||
Price-to-DCF (Earnings Based) | 1.28 | |||||
Price-to-DCF (FCF Based) | 2.17 | |||||
Price-to-Median-PS-Value | 1.02 | |||||
Price-to-Graham-Number | 4.19 | |||||
Earnings Yield (Greenblatt) % | 5.07 | |||||
FCF Yield % | 3.5 | |||||
Forward Rate of Return (Yacktman) % | 3.75 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Merck KGaA Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil CHF) | 19,468.867 | ||
| EPS (TTM) (CHF) | 5.415 | ||
| Beta | 0.5302 | ||
| 3-Year Sharpe Ratio | 0.15 | ||
| 3-Year Sortino Ratio | 0.26 | ||
| Volatility % | 52.48 | ||
| 14-Day RSI | 89.35 | ||
| 14-Day ATR (CHF) | 0.871389 | ||
| 20-Day SMA (CHF) | 124.7275 | ||
| 12-1 Month Momentum % | 1.32 | ||
| 52-Week Range (CHF) | 96.66 - 223 | ||
| Shares Outstanding (Mil) | 434.78 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Merck KGaA Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Merck KGaA Stock Events
| Event | Date | Price (CHF) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-12 | In 136 days | ||
| Third quarter earnings results for 2026 | 2026-11-12 | In 136 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 09:30 | In 39 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 07:00 | In 39 days | ||
| First quarter earnings conference call for 2026 | 2026-05-13 14:00 | 101.75 (+0.00%) | ||
| First quarter earnings results for 2026 | 2026-05-13 07:00 | 101.75 (+0.00%) | ||
| EUR 2.200000 Cash Dividend | 2026-04-27 | 105.15 (+0.00%) | ||
| General meeting for 2026 | 2026-04-24 10:00 | 105.15 (+0.00%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 14:00 | 114.60 (+0.00%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-05 07:00 | 114.60 (+0.00%) |
Show
Entries
Merck KGaA Frequently Asked Questions
What is Merck KGaA(XSWX:MER)'s stock price today?
The current price of XSWX:MER is CHF130.30. The 52 week high of XSWX:MER is CHF223.00 and 52 week low is CHF96.66.
When is next earnings date of Merck KGaA(XSWX:MER)?
The next earnings date of Merck KGaA(XSWX:MER) is 2026-08-06.
Does Merck KGaA(XSWX:MER) pay dividends? If so, how much?
The Dividend Yield %  of Merck KGaA(XSWX:MER) is 1.56% (As of Today), Highest Dividend Payout Ratio of Merck KGaA(XSWX:MER) was 0.48. The lowest was 0.2. And the median was 0.31. The  Forward Dividend Yield % of Merck KGaA(XSWX:MER) is 1.56%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Merck KGaA
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers